Oksprenolol

Oxprenolol
(IUPAC) ime
	(RS)-1-[2-(Aliloksi)fenoksi]-3-(izopropilamino)propan-2-ol
Klinički podaci
AHFS/Drugs.com	Mikromedeks, detaljne potrošačke informacije
Identifikatori
CAS broj	6452-71-7
ATC kod	C07AA02
PubChem	4631
DrugBank	DB01580
ChemSpider	4470
UNII	519MXN9YZR
KEGG	D08318
ChEMBL	CHEMBL546
Hemijski podaci
Formula	C15H23NO3
Mol. masa	265,348
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3 ; Key: CEMAWMOMDPGJMB-UHFFFAOYSA-N
Farmakokinetički podaci
Bioraspoloživost	20-70%
Metabolizam	Hepatički
Poluvreme eliminacije	1-2 sata
Izlučivanje	Renalno ; laktacijom
Farmakoinformacioni podaci
Trudnoća	C(AU)
Pravni status	℞ Prescription only
Način primene	oralno

Oksprenolol (Trasacor, Trasicor, Coretal, Laracor, Slow-Pren, Captol, Corbeton, Slow-Trasicor, Tevacor, Trasitensin, Trasidex) je neselektivni beta blokator sa intrinsičnom simpatomimetičkom aktivnošću. On se koristi za tretman angine pektoris, abnormalnog ritma srca i visokog krvnog pritiska.

Oksprenolol je lipofilni beta blokator koji prolazi kroz krvno–moždanu barijeru lakše od u vodi rastvornih blokatora. Iz tog razloga on proizvodi veći broj nuspojava u centralnom nervnom sistemu od hidrofilnih liganda atenolola, sotalola i nadolola.^[6]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ McDevitt DG (1987). „Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs”. Eur. Heart J.. 8 Suppl M: 9–14. PMID 2897304.

Povezano

Beta blokator

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] McDevitt DG (1987). „Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs”. Eur. Heart J.. 8 Suppl M: 9–14. PMID 2897304.

[1]

[2]

[3]

[4]

[5]

[6]